Company intelligence / Profile preview

Satelia

Ownership: Private
Development stage: Other

Overview

Satelia has developed an advanced digital health platform that uses algorithms and nurse-led telemonitoring to improve the management of chronic diseases such as heart failure. Their system personalizes alerts by accounting for individual patient physiology, reducing false alarms common in hospital settings. The company also emphasizes patient education to increase engagement and outcomes. As of 2025, their solution monitors half of all artificial heart patients in France[5].

Therapeutic areas: Cardiovascular
Modalities: Non-pharmacological therapy (digital/algorithmic monitoring)Device (remote monitoring platform)Service (nurse-led telemonitoring)
Industry: Digital Health Medical Devices

Partnerships

CHU de Bordeaux (academic/clinical collaboration)[5]

Beyond the preview

Go deeper on Satelia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Satelia.

Explore the full profile